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Abstract
Background The use of drugs with anticholinergic properties (DAPs) is common among older adults despite their known 
adverse effects, such as cognitive decline. Professionals should pay attention to DAPs, since evidence on their adverse effects 
has been accumulating during the last decade. However, to our knowledge previous studies exploring temporal trends in the 
use of DAPs are scarce.
Objective The aim of this study was to assess temporal trends in the use of DAPs from 2003 to 2017 in long-term care 
facilities in Helsinki.
Methods Four cross-sectional studies were conducted in 2003, 2007, 2011, and 2017. Participants included older people 
(≥ 65 years) living in nursing homes (NHs) in 2003 (n = 1979), 2011 (n = 1568), and 2017 (n = 750), and in assisted living 
facilities (ALFs) in 2007 (n = 1336), 2011 (n = 1556), and 2017 (n = 1673) in Helsinki, Finland. Data on demographics, medi-
cation use, and diagnoses were collected by structured questionnaires. The assessments were conducted as a point prevalence 
over 1 day. The use of DAPs and the total anticholinergic burden were defined by the Anticholinergic Risk Scale (ARS).
Results In ALFs, there has been an increasing trend in the use of DAPs over a 10-year period (41.2% in 2007 and 53.7% in 
2017). In NHs, by contrast, the use of DAPs remained quite stable (52.3% in 2003 and 52.4% in 2017). The burden of DAPs 
measured by ARS score decreased in NHs and remained stable in ALFs. Marked changes occurred in the DAPs used; anti-
depressants, especially mirtazapine, increased in both settings, whereas the use of hydroxyzine and urinary antispasmodics 
nearly disappeared. The proportion of users of DAP antipsychotics increased in ALFs. Participants with dementia had a 
lower anticholinergic burden than those without dementia, in both settings.
Conclusions Despite increased knowledge of the harms of DAPs, they remain widely used. Physicians seem to be aware of 
the harms of DAPs among people with dementia, and some other favorable trends in prescribing were also observed. Clini-
cians should especially consider the indications behind the use of DAP antidepressants and antipsychotics, and carefully 
weigh their potential benefits and harms.
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Key Points 
Despite their well-known adverse effects, drugs with 
anticholinergic properties (DAPs), especially antidepres-
sants and antipsychotics, remain widely used among 
older, frail people living in residential care.
Long-term care residents with dementia are being pre-
scribed less DAPs compared with those without cogni-
tive decline.
As a favorable trend, the use of some of the high-burden 
DAPs, such as hydroxyzine, has practically disappeared 
over the years.
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1 Introduction
According to recent literature, the use of drugs with anticho-
linergic properties (DAPs) among older people living in 
long-term care varies between 12 and 77%, depending on 
various populations and criteria for anticholinergic drugs 
[1–5]. The use of DAPs is common, despite adverse effects 
such as dryness of mouth and constipation [6], confusion, 
and even cognitive decline [7, 8]. There is also evidence that 
using DAPs worsens psychological well-being [5, 9]. Fur-
thermore, a greater anticholinergic load may lead to worse 
outcomes than a moderate load [6, 10, 11]. Much effort has 
been directed at defining potentially inappropriate medica-
tions (PIMs) for older people, and various lists and criteria 
have been created, such as the Beers list [12] or STOPP/
START [13]. One of the important properties of PIMs is the 
anticholinergic effect. There are also various lists defining 
DAPs [6, 14, 15]; however, no consensus has been reached 
on which of the developed criteria would be most useful in 
research or in clinical settings.
Some studies have investigated time trends in the prescrib-
ing and use of PIMs in older people [16–21]. However, to our 
knowledge, there are only a few studies examining temporal 
trends in prescribing anticholinergic drugs, and their results 
are controversial. An American register-based study investi-
gated DAP use among older NH residents with Alzheimer’s 
disease-related dementia from 2007 to 2008 [2]. The use of 
DAPs was common, although there was a small but signifi-
cant decrease in DAP use, from 77.1% in 2007 to 76.6% in 
2008. Another American study explored trends of prescribing 
high-risk anticholinergic medications between 2006 and 2015 
to older adults during outpatient visits [22]. Of medications, 
35 were determined as high-risk anticholinergics based on 
the Beers criteria and the Anticholinergic Risk Scale (ARS) 
[6]. The prevalence of high-risk anticholinergic prescriptions 
remained stable during the study period. A Scottish register-
based study [23] examined the trends of anticholinergic drug 
prescriptions to older people, from 1995 to 2010, according 
to the modified ARS. A significantly higher proportion of 
the study population received anticholinergic medication in 
2010 (23.7%) than in 1995 (20.7%). Only one of the studies 
mentioned above focused on a long-term care population, 
and in that study the study period was only 2 years. Thus, to 
our knowledge, our study is the first to investigate temporal 
trends of DAP use in long-term care over a relatively long 
period and with several assessment points.
The main objective of our study was to investigate 
14-year temporal trends in the use and burden of DAPs 
according to ARS in long-term care facilities in Helsinki. 
Another aim was to clarify temporal trends in various drug 
groups of DAPs. Furthermore, we explored how dementia 
was associated with DAP use.
2  Methods
2.1  Study Design and Population
Participants of this study were all older people perma-
nently living in nursing homes (NHs) in 2003 (n =1987), 
2011 (n =1576), and 2017 (n =791), and in assisted living 
facilities (ALFs) in 2007 (n =1377), 2011 (n =1586), and 
2017 (n =1673) in Helsinki. Written informed consent was 
obtained from every participant or their proxy in case of 
moderate–severe dementia [Clinical Dementia Rating (CDR) 
scale 2] [24]. Residents with severe dementia (CDR 2) [24] 
and not having a close proxy to give informed consent were 
excluded. The response rate in NHs was 94% in 2003, 81% 
in 2011, and 68% in 2017, while the response rate in ALFs 
was 66% in 2007, 64% in 2011, and 62% in 2017.
Residents < 65 years of age, those without medication 
charts, and those not using any drugs were excluded. After 
refusals and exclusions, 4297 subjects remained in the NH 
cohorts (2003, 2011, and 2017) and 4565 in the ALF cohorts 
(2007, 2011, and 2017).
In Finland, there are two kinds of long-term care facili-
ties—NHs and ALFs. ALFs provide care around the clock, 
but the environment is more home-like. ALFs also include 
group homes for dementia patients. Compared with ALFs, 
residents in NHs have more comorbidities and poorer cog-
nition and functioning. However, differences between the 
general state of health of residents in the two different 
settings have recently diminished [25]. The number of 
registered nurses is higher in NHs than in ALFs. The cur-
rent trend in Finland favors living at home with home-care 
assistance. Simultaneously, the number of beds has shifted 
from NHs towards ALFs, and long-term care beds in total 
have decreased.
In every participating unit, the data were gathered by 
trained registered nurses, and each resident was assessed 
over 1 day using a standardized protocol. Demographic 
data, diagnoses, and medication lists were retrieved 
from medical charts. Possible comorbid conditions were 
assessed using the Charlson Comorbidity Index (CCI) 
[26], and residents’ nutritional status was assessed using 
the Mini Nutritional Assessment (MNA) [27]. The severity 
of dementia was graded using the CDR scale [24] and its 
memory item. The ability to move was assessed using the 
MNA item (0 = bed- or wheelchair-bound; 1 = able to get 
out of bed, but does not go outside; 2 = able to go outside). 
The anticholinergic potential of medications was deter-
mined using the ARS [6], and the anticholinergic burden 
was determined using the ARS score. The ARS ranks med-
ications according to their anticholinergic potential on a 
scale ranging from 0 (no or low risk) to 3 (high anticholin-
ergic potential), and the ARS score is created by summing 
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up the points of each individual medication. Only medi-
cations used regularly were taken into consideration 
in counting the ARS score. All DAP medications were 
coded according to the Anatomical Therapeutic Chemi-
cal (ATC) classification system [28] as follows: antipsy-
chotics (N05A), antidepressants (N06A), anti-Parkinson 
drugs (N04B), urinary antispasmodics (G04BD), muscle 
relaxants (M03BX), and antihistamines for systemic use 
(R06A). Hydroxyzine (N05BB01) was studied by itself, 
and medicines for the gastrointestinal tract (metoclopra-
mide, A03FA01; loperamide, A07DA03; and ranitidine, 
A02BA02) were studied together as a group.
The study protocol was approved by the Ethics Commit-
tee of Helsinki University Hospital.
2.2  Statistical Analysis
The descriptive statistics are presented as means with 
standard deviation (SD) or counts with percentages. The 
unadjusted hypothesis of linearity was tested using the 
Cochran–Armitage test or analysis of variance with an 
appropriate contrast. Adjusted hypothesis of linearity 
(orthogonal polynomial) was evaluated using generalized 
linear models (e.g. analysis of covariance and logistic mod-
els) with appropriate distribution and link function. Mod-
els included age, sex, and CCI as covariates. The bootstrap 
method was used when the theoretical distribution of the 
test statistics was unknown or in the case of violation of the 
assumptions (e.g. non-normality). The normality of vari-
ables was evaluated using the Shapiro–Wilk W test. The 
Stata 15.1 statistical package (StataCorp LP, College Sta-
tion, TX, USA) was used for the analysis.
3  Results
In both NHs (Table 1) and ALFs (Table 2), the proportion 
of female residents has decreased over the years. The mean 
age of residents was almost 85 years and remained stable 
over the study period in both settings. In recent cohorts, 
the diagnosis of dementia became more prevalent in both 
settings and the residents were more dependent on another 
person’s assistance in mobility.
In NHs, no significant trend was observed in the mean 
number of all drugs used or in the proportion of DAP users 
over the years; however, there was a slightly decreasing 
trend in the ARS score (p <0.001). In ALFs, the mean 
number of medications increased over time (p <0.001). In 
addition, the proportion of residents using DAPs showed 
an increasing trend (p <0.001). In contrast to NHs, the 
mean ARS score did not show a decreasing trend in ALFs 
(p =0.23). We further tested the temporal trends of the use 
of ARS-defined DAPs with high anticholinergic properties 
(drugs with an ARS score of 2 or 3). In NHs, a significant 
decreasing trend was observed from 2003 (mean score 
0.59, SD 1.2) to 2011 (mean score 0.33, SD 0.9), and to 
2017 (mean score 0.29, SD 0.8) [p < 0.001]. In ALFs, no 
such trend was observed (data not shown).
The most widely used DAP drug groups defined by the 
ARS were antipsychotics and antidepressants. In NHs, an 
increasing trend in the proportion of residents using anti-
depressants was observed during 2003–2017. In antipsy-
chotics users, no significant differences were seen between 
different years in NHs. In ALFs, an increasing trend was 
observed in the users of antipsychotics and antidepres-
sants during a 10-year period. The increased use of anti-
depressants was mostly explained by the increased use of 
mirtazapine, which increased from 15.7 to 22.7% in NHs, 
and from 14.0 to 23.8% in ALFs. The use of tricyclic anti-
depressants practically disappeared, diminishing from 2.3 
to 0.3% in NHs, and from 2.0 to 0.5% in ALFs.
The use of anti-Parkinson drugs and gastrointesti-
nal drugs declined over the years in NHs, whereas use 
remained stable in ALFs. In both settings, there was a 
considerable decline in the number of users of urinary 
antispasmodics (oxybutynin and tolterodine) and hydrox-
yzine over the years studied. As a result, these medications 
were virtually phased out in 2017. Adjusting for age, sex, 
and CCI did not change the results.
To further investigate how dementia affects the use of 
DAPs, we stratified the DAP users according to diagnosis 
of dementia. In NHs, the ARS score decreased from 2003 
to 2017 (p < 0.001 for years). Residents with dementia had 
lower ARS scores than those without dementia (p < 0.001 
for dementia) and there was an interaction (p =0.003). 
Among residents in ALFs, the ARS score showed a 
slightly increasing trend during 2007–2017 for the whole 
cohort (p < 0.001 for years). Similarly, as in NHs, residents 
in ALFs with dementia had lower ARS scores (p < 0.001 
for dementia) and there was an interaction (p =0.003), thus 
indicating that the direction of the trend differs signifi-
cantly between those with and without dementia (Fig. 1).
We then stratified users of antipsychotics according to 
diagnosis of dementia. In NHs, there was no difference 
between the years (p =0.43) or between those with or with-
out dementia (p =0.42 for dementia); however, there was 
an interaction (p =0.002). In ALFs, by contrast, the propor-
tion of users of antipsychotics increased over time (p <0.001 
for years), the use was more prevalent among those with 
dementia (p <0.001 for dementia), and there was an interac-
tion (p =0.003), suggesting that there was a faster increase 
of antipsychotic use among people without dementia than 
among those with dementia (Fig. 2). Similarly, users of anti-
depressants were stratified according to diagnosis of demen-
tia. In NHs, among residents with dementia, an increasing 
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trend in users of antidepressants was observed, whereas 
among those not having a dementia diagnosis, users of 
antidepressants first increased from 2003 to 2011 and then 
decreased towards 2017 (p =0.002 for years, p =0.012 for 
dementia, p =0.005 for interaction). In ALFs, users of anti-
depressants increased over the years (p <0.001 for years), 
no significant difference was seen between those with and 
without dementia, and no interaction was present (p =0.55 
for dementia, p =0.95 for interaction) (Fig. 3).
4  Discussion
Despite the well-known harms of DAPs, approximately 
half of the residents in both long-term care settings were 
regularly administered DAPs. In ALFs, there was even an 
increasing trend in DAP users. Although the ARS score did 
not increase in ALFs, and even decreased in NHs, there was 
a worrisome increasing trend in the users of ARS-defined 
antidepressants. This was explained by the increased use of 
mirtazapine, while the use of tricyclics nearly disappeared 
over the years. In both settings, residents with dementia 
tended to have a smaller anticholinergic load than those 
without a diagnosis of dementia, indicating that physicians 
are likely to avoid prescribing DAPs to residents with cogni-
tive decline. Some other positive changes were also seen, as 
the use of ARS-defined urinary antispasmodics and hydrox-
yzine had virtually been phased out during the study period.
The main strength of this study is the large sample size 
of different cohorts within the time period examined. The 
study population is representative of the aged population 
with cognitive decline and deficits in functioning living in 
long-term care facilities. The data were collected from par-
ticipants’ medical charts by trained registered nurses using 
the same protocols, resulting in high internal validity. The 
ARS [6] is an internationally widely used set of criteria for 
describing DAPs, and it also allows calculation of the total 
anticholinergic burden. To our knowledge, this is the first 
Table 1  Characteristics of residents in nursing homes in 2003, 2011, and 2017
Data are expressed as n (%) unless otherwise specified
SD standard deviation, MNA Mini Nutritional Assessment, CCI Charlson Comorbidity Index, DAPS drugs with anticholinergic properties, ARS 
Anticholinergic Risk Scale
*p for trend; adjusted for age, sex, and CCI
a Defined by the ARS [6]
b Including metoclopramide, loperamide, and ranitidine
2003 (n =1979) 2011 (n =1568) 2017 (n =750) p for trend p for trend*
Female 1597 (80.7) 1209 (77.1) 580 (77.3) 0.013
Age, years [mean (SD)] 84 (8) 85 (8) 84 (8) 0.34
Education < 8 years 1056 (53.4) 634 (40.4) 271 (36.1) < 0.001
Prior stroke 539 (27.2) 450 (28.7) 215 (28.7) 0.57
Dementia 1374 (69.4) 1188 (76.6) 581 (77.5) < 0.001
Cancer 204 (10.3) 127 (8.1) 74 (9.9) 0.048
Bed- or wheelchair-bound 598 (30.2) 947 (60.4) 427 (56.9) < 0.001
MNA [27] 0.37
Malnourished, < 17 points 560 (28.3) 494 (31.5) 139 (18.5)
At risk for malnutrition, 17–23 points 1196 (60.4) 969 (61.8) 432 (57.6)
Well-nourished, ≥ 23.5 points 223 (11.3) 103 (6.6) 77 (10.3)
CCI [mean (SD)] [26] 2.1 (1.2) 2.4 (1.5) 2.1 (1.3) 0.39
No. of medications used regularly [mean (SD)] 7.9 (3.5) 7.3 (3.3) 8.3 (3.3) 0.94
Users of  DAPsa 1036 (52.3) 720 (45.9) 393 (52.4) 0.19 0.29
ARS score [mean (SD)] [6] 1.1 (1.5) 0.8 (1.2) 0.8 (1.1) < 0.001 < 0.001
Antipsychoticsa 633 (32.0) 419 (26.7) 245 (32.7) 0.47 0.47
Antidepressantsa 331 (16.7) 309 (19.7) 169 (22.5) < 0.001 < 0.001
Anti-Parkinson  drugsa 99 (5.0) 57 (3.6) 19 (2.5) 0.002 0.003
Urinary  antispasmodicsa 60 (3.0) 2 (0.1) 0 (0) < 0.001 < 0.001
Skeletal muscle  relaxantsa 22 (1.1) 43 (2.7) 15 (2.0) 0.013 0.014
Antihistamines for systemic  usea 7 (0.4) 20 (1.3) 2 (0.3) 0.21 0.30
Hydroxyzine 142 (7.2) 26 (1.7) 4 (0.5) < 0.001 < 0.001
Gastrointestinal  drugsa,b 44 (2.2) 13 (0.8) 7 (0.9) < 0.001 0.003
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study to explore time trends in DAP use over such a long 
period in long-term care facilities.
One limitation of the study is that the participants were 
coded, thus it was not possible to follow particular persons 
and the real changes in their medications or health status. 
However, it is known that, on average, residents live less 
than 2 years in long-term care, and thus the follow-up of a 
particular person would not be possible in any case in such 
a study. The response rate decreased over the years and is 
markedly lower in ALFs than in NHs, possibly resulting in 
some bias. There was a marked increase in the proportion of 
patients with dementia in both settings, indicating problems 
in acquiring informed consent. In addition, organizing the 
study demanded extra work from the nursing staff, which is 
the most likely reason for the lower response rates in ALFs 
than in NHs.
There is a difference in the competence of nursing staff 
between NHs and ALFs. Whereas in NHs there was a signif-
icant decrease in the use of DAPs with high anticholinergic 
properties, no such trend was observed in ALFs. During 
the years 2003–2017, there has been a transition in insti-
tutionalized care in Helsinki as the amount of beds in NHs 
have decreased and increased in ALFs. Simultaneously, the 
aim has been to enable older people to live in their homes 
longer, and the criteria to enter long-term care facilities 
have somewhat tightened. As a result, residents entering 
ALFs currently have more often cognitive decline than in 
the earlier years. During this transition, the nursing staff 
in ALFs, already being relatively smaller per resident than 
in NHs, might not have received enough education regard-
ing non-pharmaceutical approaches in the care of dementia 
patients. In NHs, the proportion of residents with dementia 
diagnosis has also increased, although not as sharply as in 
ALFs. In NHs, the nursing staff are likely to have experience 
and better know-how in taking care of residents with cog-
nitive problems and associated psychological and behavior 
problems.
Table 2  Characteristics of residents living in assisted living facilities in 2007, 2011, and 2017
Data are expressed as n (%) unless otherwise specified
SD standard deviation, MNA Mini Nutritional Assessment, CCI Charlson Comorbidity Index, DAPs drugs with anticholinergic properties, ARS 
Anticholinergic Risk Scale
*p for trend; adjusted for age, sex, and CCI
a Defined by the ARS [6]
b Including metoclopramide, loperamide, and ranitidine
2007 (n =1336) 2011 (n =1556) 2017 (n =1673) p for trend p for trend*
Female 1041 (77.9) 1217 (78.2) 1210 (72.3) < 0.001
Age, years [mean (SD)] 83 (7) 84 (7) 84 (8) 0.006
Education < 8 years 666 (49.9) 744 (47.8) 655 (39.2) < 0.001
Prior stroke 343 (25.7) 404 (26.0) 362 (21.6) 0.002
Dementia 798 (59.7) 1090 (70.1) 1302 (77.8) < 0.001
Cancer 187 (14.0) 140 (9.0) 189 (11.3) 0.19
Bed- or wheelchair-bound 195 (14.6) 446 (28.7) 508 (30.4) < 0.001
MNA [27] 0.63
Malnourished, < 17 points 167 (12.5) 311 (20.0) 243 (14.5)
At risk for malnutrition, 17–23 points 880 (65.9) 960 (61.7) 979 (58.5)
Well-nourished, ≥ 23.5 points 289 (21.6) 277 (17.8) 318 (19.0)
CCI [mean (SD)] [26] 2.1 (1.4) 2.4 (1.5) 2.0 (1.3) 0.001
No. of medications used regularly [mean (SD)] 8.3 (3.5) 8.8 (3.8) 9.0 (3.7) < 0.001
Users of  DAPsa 551 (41.2) 788 (50.6) 899 (53.7) < 0.001 < 0.001
ARS score [mean (SD)] 0.8 (1.2) 0.8 (1.1) 0.8 (1.0) 0.23 0.081
Antipsychoticsa 344 (25.7) 489 (31.4) 566 (33.8) < 0.001 < 0.001
Antidepressantsa 193 (14.4) 350 (22.5) 400 (23.9) < 0.001 < 0.001
Anti-Parkinson  drugsa 58 (4.3) 51 (3.3) 57 (3.4) 0.30 0.20
Urinary  antispasmodicsa 31 (2.3) 10 (0.6) 0 (0) < 0.001 < 0.001
Skeletal muscle  relaxantsa 17 (1.3) 13 (0.8) 25 (1.5) 0.31 0.21
Antihistamines for systemic  usea 1 (0.1) 3 (0.2) 6 (0.4) 0.091 0.10
Hydroxyzine 30 (2.2) 26 (1.7) 6 (0.4) < 0.001 < 0.001
Gastrointestinal  drugsa,b 11 (0.8) 16 (1.0) 12 (0.7) 0.56 0.69
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Our findings regarding a stable or increasing trend of 
users of DAPs is in line with previous studies [22, 23]. Con-
trary to the Scottish study [23] exploring time trends in the 
use of DAPs, the ARS score did not increase in our settings, 
and even slightly decreased in NHs. In the Scottish study, the 
residents in care homes had a higher anticholinergic burden 
than home-dwelling older people [23].
The most prevalent DAP groups in our study were antip-
sychotics and antidepressants, which is consistent with pre-
vious studies [2, 4, 22]. Among ARS-defined antidepres-
sants, mirtazapine was mostly responsible for the increase 
in antidepressant use. In addition to its antidepressant effect, 
mirtazapine has recently been used as a sedative agent for 
the treatment of insomnia, although strong evidence is lack-
ing for such off-label use, especially among people with 
dementia [29, 30]. In fact, in 2017, 86.9% of our total mir-
tazapine users in NHs and ALFs received a dose of 15 mg or 
less. According to the ARS, mirtazapine is rated as having 
moderate anticholinergic potential. Therefore, as the ARS 
burden does not consider the dose [6], the anticholinergic 
burden arising from mirtazapine use among our participants 
may be an overestimation of the true load. Nevertheless, 
physicians tend to consider mirtazapine a safer alternative 
to traditional hypnotics, and it has obviously replaced some 
of these traditional hypnotics. While mirtazapine use has 
increased, a decreasing trend in anxiolytics and hypnotics 
was observed in a Finnish study investigating the trends 
regarding the use of psychotropics [31].
The use of ARS-defined antipsychotics remained high 
compared with previous studies [4, 18, 32–34]. How-
ever, some DAP scales do not consider, for example, 
Fig. 1  Mean ARS [6] score in NH and ALF residents with and with-
out dementia, from 2003 to 2017, adjusted for age and sex. ARS 
Anticholinergic Risk Scale, NH nursing home, ALF assisted living 
facilities
Fig. 2  Users (%) of the ARS [6] defined antipsychotics in NH 
and ALF residents with and without dementia, from 2003 to 2017, 
adjusted for age and sex. ARS Anticholinergic Risk Scale, NH nursing 
home, ALF assisted living facilities
Fig. 3  Users (%) of the ARS [6] defined antidepressants in NH 
and ALF residents with and without dementia, from 2003 to 2017, 
adjusted for age and sex. ARS Anticholinergic Risk Scale, NH nursing 
home, ALF assisted living facilities
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antipsychotics, such as haloperidol, perphenazine, or risp-
eridone, having anticholinergic properties [14]. A positive 
point is that the traditional neuroleptics have been replaced 
totally by atypical antipsychotics, which have less anticho-
linergic properties and overall are considered to have less 
extrapyramidal adverse effects.
Some favorable trends in DAP use in our samples were 
observed. For example, the use of oxybutynin and toltero-
dine ceased during the study period. In an American study, 
the prevalence of urinary antispasmodics was 5.2–6% among 
the aged community-dwelling population with impaired cog-
nition [35], and, in a Norwegian NH population, antispas-
modics were used by 2.4% of the study population [18]. 
Similarly, the use of hydroxyzine has been discontinued. In 
addition, the use of gastrointestinal DAPs (metoclopramide, 
loperamide, and ranitidine) was lower than in earlier studies 
[36, 37]. However, our study did not include medications 
administered pro re nata, as did the Norwegian study in the 
case of metoclopramide [36]. Furthermore, in recent years, 
the prescribing of histamine H2-receptor antagonists has 
been replaced mainly by proton pump inhibitors.
Over the study period, the total anticholinergic burden 
decreased in NHs, but increased slightly in ALFs. The total 
DAP burden was lower among residents with dementia than 
among those without dementia. This is in line with a Nor-
wegian study in an NH population [38]. However, there are 
also controversial results, depending on the study population 
and the DAP scale used [39]. In an American study in NHs, 
dementia was negatively associated with low-level anticho-
linergic burden, but, instead, dementia increased the risk of 
high-level anticholinergic burden [4].
Our hypothesis was that the use of DAPs would have 
decreased during the 14-year follow-up due to increased 
knowledge regarding the harms of these medications. In 
some drug classes, this was the case, perhaps because there 
are well-known alternatives with less anticholinergic prop-
erties, e.g. urinary antispasmodics such as mirabegron. 
In other classes, such as antidepressants and antipsychot-
ics, there might be fewer alternative medications for older 
people.
5  Conclusions
Despite well-known harms of DAPs, approximately half of 
the residents in long-term care are administered these medi-
cations. A large proportion of old, high-burden DAPs have 
disappeared over the years, whereas mirtazapine has become 
increasingly prevalent in institutional settings. In NHs, the 
anticholinergic burden has decreased, but has remained 
stable in ALFs. A positive finding is that less DAPs were 
prescribed to residents with dementia than to those without 
dementia, suggesting that physicians are aware of the cogni-
tive adverse effects of DAPs.
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